Aprepitant Capsules

Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

Aprepitant capsules, in combination with other antiemetic agents, are indicated for the:
• prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin
• prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)

Prevention of Postoperative Nausea and Vomiting (PONV)

Aprepitant capsules are indicated for the prevention of postoperative nausea and vomiting

For indications, dosing and other information, please refer to the prescribing information.

Aprepitant Capsules ‐ Sandoz

Size:
40 mg unit of use package of 1
NDC #:
00781-2321-06
Download:
PI
Size:
40 mg unit-dose package of 5
NDC #:
00781-2321-51
Download:
PI
Size:
80 mg unit-dose package of 6
NDC #:
00781-2322-68
Download:
PI
Size:
80 mg unit of use bi-fold package of 2
NDC #:
00781-2322-46
Download:
PI
Size:
125 mg unit-dose package of 6
NDC #:
00781-2323-68
Download:
PI
Size:
125 mg unit of use tri-fold pack containing one 125 mg capsule and two 80 mg capsules
NDC #:
00781-4063-36
Download:
PI